Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial

Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial

BackgroundLiraglutide is a glucose-lowering medication used to treat type 2 diabetes and obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the incretin system, such as reducing the risk of cardiovascular complications. The understanding of these changes is critical for...

Full description

Bibliographic Details
Main Authors: Asger Wretlind, Emilie Hein Zobel, Andressa de Zawadzki, Rasmus Sejersten Ripa, Viktor Rotbain Curovic, Bernt Johan von Scholten, Ismo Matias Mattila, Tine Willum Hansen, Andreas Kjær, Henrik Vestergaard, Peter Rossing, Cristina Legido-Quigley
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Clinical Diabetes and Healthcare
Subjects:
liraglutide
GLP-1 RA
palmitoleate
palmitoleic acid
stearoyl-CoA 9-desaturase 1 (SCD1)
type 2 diabetes (T2D)
Online Access:https://www.frontiersin.org/articles/10.3389/fcdhc.2022.856485/full

Internet

https://www.frontiersin.org/articles/10.3389/fcdhc.2022.856485/full

Similar Items